Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taiwan's Biobusiness Asia Conference Draws Big Pharma Looking For Perfect Biotech Match

This article was originally published in PharmAsia News

Executive Summary

TAIPEI - Novo Nordisk's Tomas Land was in Taiwan this week hoping to give money away

You may also be interested in...



Taiwan Positions Itself As Launch Pad To China Market - BioBusiness Asia 2009 Conference

TAIPEI - Taiwan is making a serious push to create a biosciences hub. The government is not only spending plenty of money but it is also creating a welcoming regulatory environment and a relatively safe legal framework that can take some of the risk out of investing in China, speakers told BioBusiness Asia attendees in Taiwan July 21

China Paring Down Essential Medicines List In Sweeping Health System Reforms

[Editor's note: This is part three in a new series on China's wide-ranging plans to reform the country's health system, including its hospitals, insurance schemes, and access to medicines. Part one in the series appeared in PharmAsia News Oct. 30, 2008, and part two appeared Nov. 13, 2008.]

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC072270

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel